Ann: FDA Confirm Diagnostic Method on Depression Validation Trial, page-50

The management isn't good enough.

Claude's been with the company nearly 3 years.

Then :

200M shares issued
+$3M Cash in Bank
Share price $0.04
Was the biotech hot stock, covered by several analysts.

Now :

2B shares issued
+$1.7 Cash in Bank
Share price $0.003

Forget about Market Capital, right now it's just not investment proposition for any new buyers, nor existing shareholders.

Claude did CR as soon as he came on board when Medibio still had $3M sitting in bank, and every little chance he gets there's another CR, so he failed last CR, which means Mediobio is moving backwards.